Racotumomab in Patients With High-risk Neuroblastoma
Status:
Active, not recruiting
Trial end date:
2022-09-01
Target enrollment:
Participant gender:
Summary
This clinical trial will be carried out in children diagnosed with high-risk neuroblastoma
that have achieved a complete or very good partial response after standard therapy. An
additional cohort of children who could not achieve these response criteria or that relapsed
after standard therapy but do not have progressive disease will receive Racotumomab together
with metronomic chemotherapy.
The main objectives of this study are to determine the immune response after one-year
duration immunization with Racotumomab, to describe the response of Racotumomab therapy in
minimal residual disease (MRD) in bone marrow and to describe the toxicity profile of
Racotumomab.
Phase:
Phase 2
Details
Lead Sponsor:
Laboratorio Elea Phoenix S.A. Laboratorio Elea S.A.C.I.F. y A.